What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
Source record · Randomized trial · reviewed July 17, 2026
Condition-specific research exists; a general proven immune boost does not.
The circulating claim“Thymosin alpha-1 is a proven immune boost that helps people fight infections.”
What the source record says
Thymosin alpha-1 has human research in specific serious illnesses, but that does not establish a general immune benefit. In a 1,106-person phase 3 sepsis trial, 28-day mortality did not differ significantly from placebo.
Why the claim misleads
“Immune boost” merges different diseases, populations, outcomes, and products into one unmeasurable wellness promise.
Correction
Condition-specific research exists; a general proven immune boost does not.
Primary sources
Wu et al., 2025 — TESTS phase 3 trialOpen source ↗FDA thymosin alpha-1 briefingOpen source ↗Thymosin alpha-1 library entryOpen source ↗What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-17Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.